E. ÇUBUKÇU Et Al. , "Crizotinib extends survival in ALK-positive advanced NSCLC: Single center experience," Acta Oncologica Turcica , vol.52, no.3, pp.393-397, 2019
ÇUBUKÇU, E. Et Al. 2019. Crizotinib extends survival in ALK-positive advanced NSCLC: Single center experience. Acta Oncologica Turcica , vol.52, no.3 , 393-397.
ÇUBUKÇU, E., KOCA, N., KAÇAN, T., & DELİGÖNÜL, A., (2019). Crizotinib extends survival in ALK-positive advanced NSCLC: Single center experience. Acta Oncologica Turcica , vol.52, no.3, 393-397.
ÇUBUKÇU, ERDEM Et Al. "Crizotinib extends survival in ALK-positive advanced NSCLC: Single center experience," Acta Oncologica Turcica , vol.52, no.3, 393-397, 2019
ÇUBUKÇU, ERDEM Et Al. "Crizotinib extends survival in ALK-positive advanced NSCLC: Single center experience." Acta Oncologica Turcica , vol.52, no.3, pp.393-397, 2019
ÇUBUKÇU, E. Et Al. (2019) . "Crizotinib extends survival in ALK-positive advanced NSCLC: Single center experience." Acta Oncologica Turcica , vol.52, no.3, pp.393-397.
@article{article, author={ERDEM ÇUBUKÇU Et Al. }, title={Crizotinib extends survival in ALK-positive advanced NSCLC: Single center experience}, journal={Acta Oncologica Turcica}, year=2019, pages={393-397} }